Barter - Figure 13 - Secondary endpoint in ILLUMINATE Text

This next Figure shows the Kaplan Meier curves for event-free time to death in ILLUMINATE, and again the curves diverged in the wrong direction. After a median exposure to the drug of 18 months, there were 59 deaths in the atorvastatin-only arm versus 93 deaths in the combination of torcetrapib plus atorvastatin arm, a highly statistically significant 58% increase in mortality (p= 0.006). This exceeded the boundary set by the trial protocol for stopping the trial for adverse effects, and on the recommendation of the Data and Safety Monitoring Committee the trial was stopped. This was followed a few months later by 3 imaging trials that also failed to show any benefit, and all development of this particular CETP inhibitor has been stopped by Pfizer.

Barter P. J Clin Lipidol. 2011; 5(6).